What changed · written from our data
As of Nov 2, 2026Lycia Therapeutics closed at $27.18 on Nov 2, up 2.95%, 9.4% below its highest close since Oct 23.
NASDAQ · LYCA
Lycia Therapeutics, Inc. Common Stock (LYCA)
$27.18+2.95%
Close Nov 2, 2026 · split-adjustedNov 2, 2026$27.18▼ 9.40% in range
Oct 23, 2026Low $25.05 · High $30.00Nov 2, 2026
Market cap$1.42B52.1M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Oct 2325.05 – 30.00−9.4% from high
Volume271.0K
Volatility · 60d—Annualised
Short % of float—
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W −5.8%1M —3M —6M —YTD —1Y —3Y —5Y —Earnings reactions
History →No reported quarters with price history yet.
Rank within industry
Not enough peers to rank
6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—
Short interest
Details →No short interest reported.
News about Lycia Therapeutics
All news →No recent articles focused on Lycia Therapeutics.
Quick answers
- What does Lycia Therapeutics do?
- Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
- What is LYCA's market cap?
- $1.42B, based on the Nov 2 close of $27.18.
About Lycia Therapeutics
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
Listed Oct 23, 2026lyciatx.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology